TY - JOUR
TI - Deciphering anti-MOG IgG antibodies: Clinical and radiological spectrum, and comparison of antibody detection assays
AU - Tzartos, J.S.
AU - Karagiorgou, K.
AU - Tzanetakos, D.
AU - Breza, M.
AU - Evangelopoulos, M.E.
AU - Pelidou, S.-H.
AU - Bakirtzis, C.
AU - Nikolaidis, I.
AU - Koutsis, G.
AU - Notas, K.
AU - Chroni, E.
AU - Markakis, I.
AU - Grigoriadis, N.C.
AU - Anagnostouli, M.
AU - Orologas, A.
AU - Parisis, D.
AU - Karapanayiotides, T.
AU - Papadimitriou, D.
AU - Kostadima, V.
AU - Elloul, J.
AU - Xidakis, I.
AU - Maris, T.
AU - Zisimopoulou, P.
AU - Tzartos, S.
AU - Kilidireas, C.
JO - Journal of the Neurological Sciences
PY - 2020
VL - 410
TODO - null
SP - null
PB - Elsevier B.V.
SN - 0022-510X
TODO - 10.1016/j.jns.2020.116673
TODO - azathioprine;  beta interferon;  corticosteroid;  glatiramer;  immunoglobulin G antibody;  methylprednisolone;  mycophenolate mofetil;  myelin oligodendrocyte glycoprotein;  oligoclonal band;  prednisolone;  rituximab;  autoantibody;  immunoglobulin G;  myelin oligodendrocyte glycoprotein, acute disseminated encephalomyelitis;  adult;  allergic encephalitis;  antibody blood level;  antibody detection;  Article;  clinical article;  controlled study;  demyelinating disease;  encephalomyelitis;  female;  Greece;  HEK293 cell line;  human;  live cell imaging;  male;  multiple sclerosis;  myelitis;  neuroimaging;  nuclear magnetic resonance imaging;  optic neuritis;  phenotype;  pleocytosis;  priority journal;  diagnostic imaging;  myelooptic neuropathy;  optic neuritis, Autoantibodies;  Humans;  Immunoglobulin G;  Myelin-Oligodendrocyte Glycoprotein;  Neuromyelitis Optica;  Optic Neuritis
TODO - IgG antibodies to myelin oligodendrocyte glycoprotein (MOG) detected by cell based assays (CBA) have been identified in a constantly expanding spectrum of CNS demyelinating disorders. However, a universally accepted CBA has not been adopted yet. We aimed to analyze the clinical and radiological features of patients with anti-MOG IgG1-antibodies detected with a live-cell CBA and to compare the three most popular MOG-CBAs. We screened sera from 1300 Greek patients (including 426 patients referred by our 8 clinics) suspected for anti-MOG syndrome, and 120 controls with the live-cell MOG-CBA for IgG1-antibodies. 41 patients, versus 0 controls were seropositive. Clinical, serological and radiological data were available and analyzed for the 21 seropositive patients out of the 426 patients of our clinics. Their phenotypes were: 8 optic neuritis, 3 myelitis, 3 neuromyelitis optica, 2 encephalomyelitis, 2 autoimmune encephalitis and 3 atypical MS. We then retested all sera of our 426 patients with the other two most popular MOG-CBAs for total IgG (a live-cell and a commercial fixed-cell CBAs). Seven IgG1-seropositive patients were seronegative for one or both IgG-CBAs. Yet, all 21 patients had clinical and radiological findings previously described in MOG-antibody associated demyelination disease supporting the high specificity of the IgG1-CBA. In addition, all IgG1-CBA-negative sera were also negative by the IgG-CBAs. Also, all controls were negative by all three assays, except one serum found positive by the live IgG-CBA. Overall, our findings support the wide spectrum of anti-MOG associated demyelinating disorders and the superiority of the MOG-IgG1 CBA over other MOG-CBAs. © 2020 Elsevier B.V.
ER -